The funds raised will be directed towards generating clinical proof-of-concept for BE-101 in the ongoing BeCoMe-9 Phase I/II trial. Credit: skipper_sr/Shutterstock.

Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and hypophosphatasia.

New investor Nextech participated in the round, which also received contributions from current investors such as Bristol Myers Squibb, ARCH Venture Partners, RA Capital Management, Atlas Ventures and Alta Partners.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The funds will be directed towards generating clinical proof-of-concept for the company’s B cell medicine (BCM), BE-101, in the BeCoMe-9 Phase I/II trial underway for individuals with haemophilia B.

The proceeds will support the advancement of BE-102, a treatment for hypophosphatasia, into clinical testing.

Both programmes are underpinned by the company’s BCM product platform.

The company has also announced that Melissa McCracken from Nextech, a Switzerland-based venture capital firm, will join the board of directors of Be Bio.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Be Bio CEO Joanne Smith-Farrell stated: “With this funding in hand, we are well-equipped to advance our two lead programmes and solidify our position as a multi-programme, clinical-stage company.

“We are on track to demonstrate clinical proof-of-concept for BE-101 in haemophilia B this year.  Additionally, BE-102 is poised to enter the clinic next year, potentially demonstrating BCMs’ potential to become a new gold standard in enzyme replacement by providing hypophosphatasia patients with a transformative new option.”

BE-101 is designed to continuously express active Factor IX (FIX) following a single infusion. The US Food and Drug Administration granted investigational new drug clearance in May 2024 followed by fast track status in September.

Another BCM targeting hypophosphatasia (HPP), BE-102 leverages artificial intelligence-guided protein design for modifying primary human B cells to produce the alkaline phosphatase enzyme, which is deficient in individuals with HPP.